ROSEN Law Firm Urges Telix Pharmaceuticals Investors to Act Before January 9, 2026 Deadline

On November 16, 2025, the global investor‑rights firm Rosen Law Firm announced it has filed a class‑action lawsuit on behalf of purchasers of the securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) who bought shares between February 21, 2025 and August 28, 2025 (inclusive). The law firm advises those investors that if they wish to serve as lead plaintiff in the litigation, they must file a motion with the Court by January 9, 2026. According to the complaint, Telix allegedly made materially false or misleading statements and/or failed to disclose key facts during the class period, including: The company’s purported progress with prostate‑cancer therapeutic candidates was overstated. The quality of the company’s supply chain and business partners was misrepresented. As a result, investor losses are alleged when the true facts entered the market. Investors who acquired Telix securities during the class period may be eligible for compensation under a contingency‑fee basis, meaning no upfront cost. The Rosen Law Firm emphasises the importance of choosing experienced counsel with a proven track‑record of leading major securities class actions. #TelixPharmaceuticals #SecuritiesClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM